May 12, 2004



Mr. Brice Nelson

The University of Michigan

Office of Technology Transfer

Wolverine Tower, Room 2071

3003 S. State Street

Ann Arbor, MI  48109-1280



Attn:  File No. 1061



Dear Brice,



To reflect the realities of staffing and funding resources, I am writing to request amendment to the License Agreement between Genesis Bioventures, Inc. and The University of Michigan (File No. 1061). The following modifications in Section 5.3 (Milestones) are requested:



| | 1. | Milestone (2):  Characterization of target protein(s) based on verifiable protein sequence(s).
| | -- | ----------------------------------------------------------------------------------------------



We request the milestone date be moved from May 15, 2004 to February 15, 2005.



| | 2. | Milestone (3):  The filing of an FDA application for the current format OR Adoption of an improved alternate diagnostic format (such as ELISA).
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------



We request the milestone date be moved from November 15, 2004 to May 15, 2005.



| | 3. | Milestone (4):  Cumulative NET SALES of at least $25,000.
| | -- | ---------------------------------------------------------



We request the milestone date be moved from May 15, 2005 to November 15, 2005.



| | 4. | Milestone (5):  Cumulative NET SALES of at least $100,000.
| | -- | ----------------------------------------------------------



We request the milestone date be moved from May 15, 2006 to November 15, 2006.



| | 5. | Milestone (6):  Increased employee staffing levels from those on May 15, 2004, including a senior regulatory person, 5 scientists (including medical technicians) and a viable customer service function (the last of which may be contracted out).
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



We request the milestone date be moved from May 15, 2005 to November 15, 2005.



| | 6. | Milestone (7):  FDA approval of improved alternate diagnostic format (such as ELISA) OR FDA approval of current diagnostic format.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------



We request the two milestone dates be moved from May 15, 2009 to November 15, 2009 and from May 17, 2007 to November 15, 2007, respectively.



Please note that Milestone (1): FIRST COMMERCIAL SALE by October 15, 2003 was completed on schedule as previously reported to you.





---







Mr. Brice Nelson

The University of Michigan

Office of Technology Transfer

May 12, 2004

Page 2 of 2





Thank you for your consideration on this amendment. If you agree to these modifications, please indicate your approval below. Meanwhile, please contact me if you have any questions.





|Sincerely, | Signed and agreed:
|---------- | ------------------



|GENESIS BIOVENTURES, INC. | THE UNIVERSITY OF MICHIGAN
|------------------------- | --------------------------







|_________________________________ | _____________________________________
|--------------------------------- | -------------------------------------

E. Greg McCartney

|Chairman/CEO | Printed Name: _________________________
|------------ | ---------------------------------------



| | Title:  ________________________________
| | ----------------------------------------



| | Date:  ________________________________
| | ---------------------------------------









CC:  James S. Arthurs, Biomedical Diagnostics, LLC